{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:35:38Z","timestamp":1792467338453,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T00:00:00Z","timestamp":1433462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejca.2015.05.016","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T08:59:11Z","timestamp":1434531551000},"page":"1812-1821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"title":["Hypocalcaemia in patients with metastatic bone disease treated with denosumab"],"prefix":"10.1016","volume":"51","clinical-trial-number":[{"clinical-trial-number":"nct00321464","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00321620","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00330759","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jean-Jacques","family":"Body","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry G.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Stopeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Van Poznak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"Dami\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Shaywitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswaldo L.","family":"Bracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kostenuik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.05.016_b0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/era.11.204","article-title":"Denosumab for the management of bone disease in patients with solid tumors","volume":"12","author":"Body","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2015.05.016_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2015.05.016_b0015","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2015.05.016_b0020","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(87)90255-8","article-title":"Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate","volume":"1","author":"Jodrell","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.05.016_b0025","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.05.016_b0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eururo.2013.05.015","article-title":"Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappaB ligand inhibitors in patients with advanced prostate cancer","volume":"65","author":"Gartrell","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2015.05.016_b0035","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.016_b0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3816\/CGC.2007.n.025","article-title":"Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases","volume":"5","author":"Gulley","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2015.05.016_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0885-3924(02)00644-9","article-title":"Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports","volume":"25","author":"Champallou","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.ejca.2015.05.016_b0050","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa0810925","article-title":"Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin","volume":"361","author":"Riches","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2015.05.016_b0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1248\/bpb.33.721","article-title":"Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor","volume":"33","author":"Hanamura","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ejca.2015.05.016_b0060","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.016_b0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.05.016_b0070","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.016_b0075","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). <http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf>; 2006 [accessed 06.06.14]."},{"key":"10.1016\/j.ejca.2015.05.016_b0080","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","article-title":"The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy","volume":"146","author":"Morony","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejca.2015.05.016_b0085","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2015.05.016_b0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-009-0119-x","article-title":"A review of drug-induced hypocalcemia","volume":"27","author":"Liamis","year":"2009","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.ejca.2015.05.016_b0095","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2008.12.004","article-title":"Safety of bisphosphonates in the treatment of osteoporosis","volume":"122","author":"Recker","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.ejca.2015.05.016_b0100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1634\/theoncologist.2008-0227","article-title":"High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid","volume":"14","author":"Zuradelli","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2015.05.016_b0105","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.016_b0110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2015.05.016_b0115","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1185\/03007995.2013.813840","article-title":"Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies","volume":"29","author":"Qi","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejca.2015.05.016_b0120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2015.05.016_b0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ejca.2015.05.016_b0130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2012.06.019","article-title":"Severe hypocalcemia following denosumab injection in a hemodialysis patient","volume":"60","author":"McCormick","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejca.2015.05.016_b0135","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJM200304103481521","article-title":"Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency","volume":"348","author":"Rosen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2015.05.016_b0140","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bone.2006.04.032","article-title":"Severe hypocalcemia following bisphosphonate treatment in a patient with Paget\u2019s disease of bone","volume":"39","author":"Whitson","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.ejca.2015.05.016_b0145","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2015.05.016_b0150","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jbmr.2401","article-title":"Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys","volume":"30","author":"Kostenuik","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2015.05.016_b0155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF02556053","article-title":"Some ABCs of skeletal pathophysiology. III: Bone balance and the delta B.BMU","volume":"45","author":"Frost","year":"1989","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ejca.2015.05.016_b0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","article-title":"Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"49","author":"Kostenuik","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ejca.2015.05.016_b0165","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.79.10.3325","article-title":"1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis","volume":"79","author":"Gallagher","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2015.05.016_b0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1022994104070","article-title":"Emergencies of calcium homeostasis","volume":"4","author":"Body","year":"2003","journal-title":"Rev Endocr Metab Disord"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915004475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915004475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T14:52:08Z","timestamp":1537541528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915004475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0959804915004475"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}